The offering follows positive clinical data, suggesting confidence in the pipeline. The substantial capital raise combined with strong cash position provides runway for multiple clinical programs. Traders should monitor enrollment in Part B of the SKYLINE trial and upcoming data readouts for SPY002 and SPY003.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $64.01entry
- T+1 · 7mo ago +7.78%α +7.01% · $68.99
- T+5 · 7mo ago +11.34%α +9.95% · $71.27
- T+20 · 6mo ago +19.40%α +13.11% · $76.43
- T+60 · 4mo ago +54.27%α +45.75% · $98.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics is raising $300 million through a common stock offering, following positive Phase 2 topline data for its lead candidate SPY001 in ulcerative colitis. The company reported preliminary cash of $741 million as of March 31, 2026, and has terminated its prior ATM offering. The capital will fund ongoing clinical programs in inflammatory bowel and rheumatic diseases.
Key Facts
- Spyre Therapeutics is offering $300 million of common stock
- Positive Phase 2 topline data for SPY001 in ulcerative colitis showed statistically significant reduction in RHI score of 9.2 points (p<0.0001)
- Company reported preliminary cash of $741 million as of March 31, 2026
- Terminated prior ATM offering in connection with this new offering
- Proceeds will fund clinical programs in IBD and rheumatic diseases
- Stock priced at $51.29 per share on April 10, 2026, prior to announcement
Financial Impact
Raises $300 million in gross proceeds, with net proceeds to be used for advancing clinical programs. Company had $741 million in cash as of March 31, 2026.
Risk Factors
- Dilution to existing shareholders from the $300 million offering
- Clinical trial risks for ongoing and future studies
- Competition in the IBD and rheumatic disease markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-024940 |
| Document: 0001628280-26-024940-index-headers.html | 0001628280-26-024940 |
| Document: 0001628280-26-024940-index.html | 0001628280-26-024940 |
| Document: 0001628280-26-024940.txt | 0001628280-26-024940 |
Track record
36 reports on SYRE
7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +50.78% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers